Terapia imunológica com inibidor da interleucina-17 no tratamento de psoríase vulgar

Abstract

Psoriasis is a chronic systemic inflammatory disease with a major impact on patients' quality of life. The most common presentation is plaque psoriasis or psoriasis vulgaris. Mild illnesses are treated initially with topical medications, while moderate/severe conditions may have topical therapy associated with phototherapy and possibly combined with systemic therapy or the option of using immunobiological agents. The use of immunobiologicals has been shown to be a good option for the treatment of moderate/severe psoriasis, presenting better results in reducing the symptoms and improving the quality of life of the patient. Among the immunobiological drugs inhibiting IL-17 are secukinumab, ixekizumab and brodalumab. Objectives: To verify the efficacy of the use of IL-17 inhibitors (secukinumab, brodalumab and ixekizumab) in the treatment of moderate to severe psoriasis. Conclusion: Ixekizumab was considered the most effective immunobiological in the short-term treatment for moderate to severe plaque psoriasis in terms of PASI 75 and PASI 90, followed by Secukinumab and Brodalumab. Although the short-term effects of biological agents on moderate to severe psoriasis are well documented, studies examining long-term efficacy and safety are more limited and need better evaluation.